A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Aug 10, 2026 → Dec 15, 2026
See other at-risk trials from Boehringer Ingelheim

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 30, 2026 to Dec 15, 2026
    • Study completion date: Dec 25, 2026 to Jan 15, 2027
    • Eligibility criteria expanded, about 24 words
  2. Primary completion pushed from Aug 10, 2026 to Sep 30, 2026
    • Study completion pushed from Nov 25, 2026 to Dec 25, 2026
    v13
  3. Primary completion date: May 18, 2026 to Aug 10, 2026v12
  4. Primary completion date: Jan 18, 2026 to May 18, 2026
    • Study completion date: Jul 25, 2026 to Nov 25, 2026
    v11
  5. Start date: Feb 22, 2024 to Aug 6, 2024v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v8
  3. Start date: Jan 31, 2024 to Feb 22, 2024v7
  4. Re-verified, no change to tracked fieldsv6
  5. Start date: Nov 16, 2023 to Jan 31, 2024v5
  6. Primary completion date: Dec 21, 2025 to Jan 18, 2026
    • Study completion date: Jun 27, 2026 to Jul 25, 2026
    • Start date: Oct 19, 2023 to Nov 16, 2023
    v4
  7. Start date: Aug 24, 2023 to Oct 19, 2023
    • Primary completion date: Oct 26, 2025 to Dec 21, 2025
    • Study completion date: May 2, 2026 to Jun 27, 2026
    v3
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is open to adults with small cell lung cancer and other neuroendocrine cancers. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out how a medicine called BI 764532 gets distributed in the body and in tumours. Participants get BI 764532 when starting treatment. In the first weeks, doctors check how BI 764532 is taken up in tumours by means of an imaging method. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Trial Details
NCT Number NCT05963867
Lead Sponsor Boehringer Ingelheim
Conditions
(from sponsor)		 Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
Related terms Small Cell Lung Carcinoma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov